About Us : Leadership : Board of Directors
Chairman of FORMA Therapeutics Board of Directors
Peter Wirth served Genzyme Corporation as Secretary to the Board of Directors and outside general counsel from 1982 until its acquisition by Sanofi. From January 1996 through May 2011, he was a senior executive at Genzyme, most recently serving as Executive Vice President, Legal and Corporate Development, Chief Risk Officer and Corporate Secretary. During this time, Mr. Wirth had senior management responsibility for Genzyme’s legal function, its corporate development function, its molecular oncology tracking stock division (Nasdaq: GZMO), its non-absorbed polymer drug discovery and development division and its enterprise risk management function. Mr. Wirth worked closely with Henri Termeer, Genzyme’s CEO, to build the company from a small start-up to a diversified enterprise with more than 12,000 employees in locations spanning the globe and 2009 revenues of $4.5 billion. Genzyme was named a Fortune 500 company in 2010 and was acquired by Sanofi-Aventis in a transaction valued at more than $20 billion in April 2011.
From 1975 through 1995, Mr. Wirth practiced law at Palmer & Dodge, a Boston law firm, where he was head of the firm’s biotechnology practice group. Mr. Wirth acted as outside general counsel for a number of public and private biotechnology companies, including companies working in the areas of neuroscience, immunology, non-absorbable pharmaceuticals, gene therapy, structure-based drug design, NMR imaging agents, and bioseparations. Mr. Wirth also acted as special outside counsel to biotechnology and pharmaceutical companies in the area of corporate collaborations and joint ventures. His areas of legal expertise include venture capital financings, institutional private placements, public offerings, off-balance sheet R&D financings such as RDLPs and SWORDS, corporate collaborations, joint ventures and mergers and acquisitions.
Mr. Wirth was a 2012 Advanced Leadership Fellow at Harvard University. He received his B.A. from the University of Wisconsin – Madison in 1972 and his J.D. from Harvard Law School in 1975. He currently serves as a Director of Synageva BioPharma Corp. (Nasdaq: GEVA).
Global Head of the Novartis Venture Funds
He is the Executive Director of the Novartis Venture Funds. Previously, he worked with Novartis Corporate Finance where he held the position of Head of Group Strategic Planning for several years. He was responsible for post merger integrations at Novartis Corporate M&A and was Global Head BD&L Cardiovascular and Metabolic Diseases and Novartis Pharma. Earlier in his career he had global leadership positions for key drug development projects at Novartis and Roche. He trained as a pharmacist, Ph.D. in medicinal chemistry and pharmacology and focused postdoctoral training in clinical pharmacology. Selected other board memberships are at Cylene, Genedata, Symetis and Tokai.
Board of Director (FORMA Therapeutics; Alnylym Pharmaceuticals; Ironwood Pharmaceuticals; Momenta Pharmaceuticals)
From 2000 to 2009, Ms. Fanucci served at Millennium Pharmaceuticals in a number of executive leadership positions, including Chief Financial Officer and Senior Vice President of Strategy, Vice President of Finance and Strategy, and Vice President of Corporate Development and Strategy. During her tenure, Ms. Fanucci directly contributed to a series of strategic processes, advanced investment-stage Millennium to profitability and was instrumental in the acquisition by Takeda Pharmaceutical Company in 2008 for $8.8 billion. Previously, Ms. Fanucci was Vice President of Corporate Development and Strategy at Genzyme Corporation and Vice President and Director at Arthur D. Little. Ms. Fanucci serves on the boards of directors of Alnylam Pharmaceuticals, Ironwood Pharmaceuticals and Momenta Pharmaceuticals. Ms. Fanucci received a B.S. in pharmacy from West Virginia University Medical School and an M.B.A. from Northeastern University
Academic Founder, FORMA Therapeutics; Sanders Director, Tri-Institutional Therapeutics Discovery Institute; Director, Sanders Innovation and Education Initiative
Michael A. Foley, Ph.D., has been selected to lead the Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI), a pioneering collaboration of Weill Cornell Medical College, The Rockefeller University and Memorial Sloan Kettering Cancer Center that is designed to expedite early-stage drug discovery into novel treatments for patients.
Dr. Foley’s title is the Sanders Director of Tri-I TDI and Director of the Sanders Innovation and Education Initiative, in recognition of the $15 million gift from Lewis and Ali Sanders to help establish the Institute. An accomplished chemist and entrepreneur with more than 25 years of industry and academic experience, Dr. Foley is scientific co-founder of four companies and one academic institute and has placed 12 single-agent or combination drugs into clinical development. He was most recently the Director of the Chemical Biology Platform at the Broad Institute of Harvard and MIT.
Dr. Foley previously worked at Bristol-Myers Squibb and GlaxoSmithKline, and obtained his Ph.D. in chemistry at Harvard.
Venture Partner at Lilly Ventures
Steve brings more than 25 years of pharmaceutical experience from both multinational pharmaceutical companies and biotech organizations to Lilly Ventures. Prior to joining Lilly Ventures, Steve was co-founder and Senior Vice President, R&D of Serenex, Inc. In this role, he recruited and led a team in developing a novel discovery technology that advanced the target program from a novel screen to first patient dosed in just over three years. This novel orally-active Hsp90 inhibitor was the subject of strong interest across the industry and led to the acquisition of Serenex by Pfizer in April 2008. Before joining Serenex, Steve was Site Director, Sphinx Labs, Eli Lilly where he oversaw lead generation efforts in the areas of combinatorial chemistry, automation, high-throughput screening, biomolecular research, and information technology. He was a key member of a small team that developed and executed a strategy to partner Lilly’s expertise in high-throughput chemistry with three Japanese pharmaceutical companies with an aggregate value of more than $75MM. Steve received his BS in chemistry from Central Michigan University and his PhD in organic chemistry from the Massachusetts Institute of Technology, and is the author of more than 40 papers and an inventor on greater than 60 patents. Steve currently sits on the board of Hydra Biosciences, and serves as a board observer at Avid Radiopharmaceuticals and Viamet Pharmaceuticals.
Board of Director
Dr. Paoletti is currently the Chief Executive Officer of Kesios Therapeutics, a UK-based biotechnology company developing novel therapeutics for the treatment of multiple myeloma and other cancers. He recently held several executive leadership roles in oncology at GSK, including Head of Oncology Research and Discovery Unit, Member of the Executive Board for Portfolio Investment and Chairman of the Oncology Portfolio Board. In his global leadership roles, he maintained the accountability for GSK’s entire oncology business and was responsible for drug discovery from target identification through registration, including product life cycle management and commercial strategy. Throughout his pharmaceutical tenure at GSK, he led the global approval of seven new medicines to treat different cancers, originated a global oncology business integrating regional plans and responsibilities, and led the development of the first novel–novel combination of agents to registration with the FDA. Prior to joining GSK Oncology in 2004, Dr. Paoletti served in roles of increasing leadership responsibility at Eli Lilly in Indianapolis, where he was most recently Vice President, Oncology. He received his M.D. from University of Pisa, Italy, and he was a NIH Fogarty fellow at the University of Arizona. Dr. Paoletti has authored over 350 scientific publications.
Founder, President and CEO, FORMA Therapeutics
Prior to founding FORMA, Steven Tregay was a Managing Director for the $200M Novartis Option Fund. He led the fund’s investments in and served on the Board of Directors of FORMA Therapeutics, Adenosine Therapeutics (acquired by Clinical Data: FRX) and Cequent Pharmaceuticals (acquired by Marina Biotech: MRNA). Prior to joining the venture group, he was the Executive Director and Head of Strategic Alliances-Oncology, Ophthalmology and Technologies at the Novartis Institutes for BioMedical Research. He managed a team who were responsible for identification, negotiation and management of collaborations for the oncology and ophthalmology disease areas and all the technology areas. Prior to Novartis, he had roles in business development at Array BioPharma and research. He received his Ph.D. and M.S. in organic chemistry from Harvard University and a B.S. from Davidson College.
Scientific Advisory Board